AstraZeneca Pharma India Limited (ASTRAZEN.BO)
INR 8061.9
(2.24%)
INR 8061.9
(2.24%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.61 Billion INR | 62.66% |
| 2022 | 992.9 Million INR | 61.19% |
| 2021 | 616 Million INR | -33.98% |
| 2020 | 933 Million INR | 29.21% |
| 2019 | 722.1 Million INR | 32.62% |
| 2018 | 544.5 Million INR | 110.15% |
| 2017 | 259.1 Million INR | 29.23% |
| 2016 | 200.5 Million INR | 281.25% |
| 2015 | 52.58 Million INR | 125.24% |
| 2014 | -208.39 Million INR | -3994.91% |
| 2013 | -5.08 Million INR | 99.43% |
| 2012 | -895.32 Million INR | -552.98% |
| 2011 | 197.65 Million INR | -69.18% |
| 2010 | 641.29 Million INR | 11.3% |
| 2009 | 576.17 Million INR | -21.97% |
| 2008 | 738.35 Million INR | 20.14% |
| 2007 | 614.58 Million INR | 26.1% |
| 2006 | 487.36 Million INR | 13.19% |
| 2005 | 430.58 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -117.9 Million INR | -129.86% |
| 2023 Q2 | 523.69 Million INR | -2.77% |
| 2023 Q1 | 538.6 Million INR | 211.89% |
| 2023 Q4 | 394.78 Million INR | 149.85% |
| 2023 Q3 | 158 Million INR | -69.83% |
| 2023 FY | 1.61 Billion INR | 62.66% |
| 2022 Q3 | 293.04 Million INR | -10.01% |
| 2022 Q4 | 172.68 Million INR | -41.07% |
| 2022 Q1 | 201.52 Million INR | -28.0% |
| 2022 Q2 | 325.64 Million INR | 61.59% |
| 2022 FY | 992.9 Million INR | 61.19% |
| 2021 Q3 | 114.19 Million INR | -4.42% |
| 2021 Q4 | 279.9 Million INR | 145.12% |
| 2021 FY | 616 Million INR | -33.98% |
| 2021 Q1 | 102.43 Million INR | -62.44% |
| 2021 Q2 | 119.47 Million INR | 16.63% |
| 2020 Q2 | 263.38 Million INR | 41.34% |
| 2020 FY | 933 Million INR | 29.21% |
| 2020 Q4 | 272.75 Million INR | 29.56% |
| 2020 Q3 | 210.51 Million INR | -20.07% |
| 2020 Q1 | 186.34 Million INR | 94.56% |
| 2019 Q1 | 215.15 Million INR | 118.8% |
| 2019 Q2 | 144.15 Million INR | -33.0% |
| 2019 Q3 | 267.01 Million INR | 85.23% |
| 2019 Q4 | 95.77 Million INR | -64.13% |
| 2019 FY | 722.1 Million INR | 32.62% |
| 2018 FY | 544.5 Million INR | 110.15% |
| 2018 Q3 | 290.91 Million INR | 218.58% |
| 2018 Q4 | 98.33 Million INR | -66.2% |
| 2018 Q1 | 63.93 Million INR | 98.47% |
| 2018 Q2 | 91.31 Million INR | 42.83% |
| 2017 Q4 | 32.21 Million INR | 131.12% |
| 2017 Q3 | -103.52 Million INR | -137.8% |
| 2017 Q2 | 273.84 Million INR | 372.37% |
| 2017 Q1 | 57.97 Million INR | 160.64% |
| 2017 FY | 259.1 Million INR | 29.23% |
| 2016 Q2 | 8.02 Million INR | -93.63% |
| 2016 Q4 | -95.59 Million INR | -158.97% |
| 2016 Q3 | 162.1 Million INR | 1919.99% |
| 2016 FY | 200.5 Million INR | 281.25% |
| 2016 Q1 | 126.01 Million INR | 2161.23% |
| 2015 FY | 52.58 Million INR | 125.24% |
| 2015 Q4 | 5.57 Million INR | -93.58% |
| 2015 Q3 | 86.74 Million INR | 229.68% |
| 2015 Q2 | -66.89 Million INR | -346.24% |
| 2015 Q1 | 27.16 Million INR | -92.88% |
| 2014 Q4 | 381.29 Million INR | 384.36% |
| 2014 FY | -208.39 Million INR | -3994.91% |
| 2014 Q1 | -176 Million INR | -585.15% |
| 2014 Q2 | -279.6 Million INR | -58.86% |
| 2014 Q3 | -134.09 Million INR | 52.04% |
| 2013 Q4 | -25.68 Million INR | -269.25% |
| 2013 FY | -5.08 Million INR | 99.43% |
| 2013 Q1 | 17.68 Million INR | 109.52% |
| 2013 Q2 | -12.26 Million INR | -169.35% |
| 2013 Q3 | 15.17 Million INR | 223.76% |
| 2012 Q3 | -176.95 Million INR | 60.78% |
| 2012 Q2 | -451.15 Million INR | -453.84% |
| 2012 Q1 | -81.46 Million INR | 75.32% |
| 2012 FY | -895.32 Million INR | -552.98% |
| 2012 Q4 | -185.75 Million INR | -4.97% |
| 2011 Q4 | -330.04 Million INR | -320.95% |
| 2011 Q3 | 149.37 Million INR | 0.0% |
| 2011 FY | 197.65 Million INR | -69.18% |
| 2010 FY | 641.29 Million INR | 11.3% |
| 2009 FY | 576.17 Million INR | -21.97% |
| 2008 FY | 738.35 Million INR | 20.14% |
| 2007 FY | 614.58 Million INR | 26.1% |
| 2006 FY | 487.36 Million INR | 13.19% |
| 2005 FY | 430.58 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 73.773% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 94.91% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 65.701% |
| Granules India Limited | 4.05 Billion INR | 60.151% |
| Indoco Remedies Limited | 984.6 Million INR | -64.036% |
| Achyut Healthcare Limited | 5.73 Million INR | -28076.902% |
| Ajanta Pharma Limited | 8.16 Billion INR | 80.211% |
| Alkem Laboratories Limited | 17.95 Billion INR | 91.006% |
| Alpa Laboratories Limited | 167.76 Million INR | -862.716% |
| Brooks Laboratories Limited | -195.91 Million INR | 924.371% |
| Bajaj HealthCare Limited | -837.93 Million INR | 292.749% |
| Bliss GVS Pharma Limited | 754.54 Million INR | -114.051% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 97.1% |
| Eris Lifesciences Limited | 3.91 Billion INR | 58.797% |
| FDC Limited | 3.05 Billion INR | 47.085% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 110.755% |
| Gufic Biosciences Limited | 861.35 Million INR | -87.507% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 61.633% |
| Ipca Laboratories Limited | 5.47 Billion INR | 70.492% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -619.005% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 918.668% |
| Lasa Supergenerics Limited | -217.3 Million INR | 843.238% |
| Laurus Labs Limited | 1.6 Billion INR | -0.598% |
| Lupin Limited | 19.14 Billion INR | 91.564% |
| Mankind Pharma Limited | 19.12 Billion INR | 91.557% |
| Medicamen Biotech Limited | 109.31 Million INR | -1377.541% |
| Medico Remedies Limited | 82.9 Million INR | -1848.039% |
| Megasoft Limited | -127.46 Million INR | 1367.083% |
| NATCO Pharma Limited | 13.88 Billion INR | 88.366% |
| Piramal Pharma Limited | 178.2 Million INR | -806.341% |
| RPG Life Sciences Limited | 876.6 Million INR | -84.246% |
| Sigachi Industries Limited | 571.8 Million INR | -182.458% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 98.313% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 46.214% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -538.021% |
| Unichem Laboratories Limited | -704.74 Million INR | 329.176% |
| Wanbury Limited | 559.56 Million INR | -188.636% |
| Windlas Biotech Limited | 581.87 Million INR | -177.571% |
| ZIM Laboratories Limited | 172.46 Million INR | -836.485% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 95.815% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 141.711% |
| Divi's Laboratories Limited | 16 Billion INR | 89.906% |
| Hester Biosciences Limited | 188.89 Million INR | -755.048% |
| Procter & Gamble Health Limited | 2 Billion INR | 19.639% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -259.13% |
| Bal Pharma Limited | 73.92 Million INR | -2084.871% |
| Strides Pharma Science Limited | -706.14 Million INR | 328.722% |
| Venus Remedies Limited | 284.9 Million INR | -466.885% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 25.538% |
| Nectar Lifesciences Limited | 49.95 Million INR | -3133.433% |
| Shilpa Medicare Limited | 318.74 Million INR | -406.711% |
| Aarti Drugs Limited | 1.71 Billion INR | 5.78% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | -20.144% |
| Suven Life Sciences Limited | -1.05 Billion INR | 253.707% |
| Ind-Swift Limited | 142.31 Million INR | -1034.893% |
| Valiant Laboratories Limited | 3.19 Million INR | -50435.044% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 70.774% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 128.465% |
| Themis Medicare Limited | 435.23 Million INR | -271.084% |
| Hikal Limited | 696.02 Million INR | -132.048% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 90.249% |
| Sequent Scientific Limited | -358.69 Million INR | 550.277% |
| Novartis India Limited | 851.9 Million INR | -89.588% |
| Wockhardt Limited | -4.63 Billion INR | 134.883% |
| Jubilant Pharmova Limited | 771 Million INR | -109.481% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -22673.548% |
| Neuland Laboratories Limited | 3 Billion INR | 46.177% |
| Morepen Laboratories Limited | 961.59 Million INR | -67.96% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -1006.127% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 1880.372% |